Login
$PLSE
$46.36 -$4.08 (8.09%) Live

$PLSE SEC Filings

Filed On Filing
06 Nov 2026 8-K: Other Events

Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting

05 Nov 2026 FORM 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Completed enrollment of NANOPULSE-AF US IDE pivotal study for treatment of AF with nPulse Cardiac Catheter System

14 Oct 2026 8-K: Other Events

Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data

07 Oct 2026 8-K: Other Events

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

15 Sep 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar...

15 Sep 2026 FORM 424B5
15 Sep 2026 8-K: Other Events

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

02 Sep 2026 Form 4: Teplitsky Liane Rae, Chief Operating Officer

Bought 1,024 shares ($50K) · Bought 1,001 shares ($50K)

28 Aug 2026 Form 4: Teplitsky Liane Rae, Chief Operating Officer

Bought 1,036 shares ($50K) · Bought 1,034 shares ($50K)

28 Aug 2026 Form 4: Teplitsky Liane Rae, Chief Operating Officer

Granted 200,000 Restricted Stock Units · Granted 700,000 Stock Option (right to buy)

28 Aug 2026 Form 3: Teplitsky Liane Rae, Chief Operating Officer

No securities owned

28 Aug 2026 Form 4: Skinner Jon, Chief Financial Officer

Granted 300,000 Stock Option (right to buy)

28 Aug 2026 Form 3: Skinner Jon, Chief Financial Officer

No securities owned

06 Aug 2026 8-K: Entry into a Material Definitive Agreement

Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar...

06 Aug 2026 FORM 424B5
06 Aug 2026 FORM 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

HAYWARD, California [Business Wire] — August 6, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business upda...

29 Jul 2026 8-K: Other Events

HAYWARD, California, July 29, 2026 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study ha...

15 Jun 2026 Form 4: Zanganeh Mahkam, Director

Granted 44,504 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support